Nasus Pharma Ltd.
As of Oct 22, 2026, Nasus Pharma is in Stage 1, the basing phase, now in week 18 (since Jun 17, 2026). It closed at $3.23, 64.7% below its 52-week high and below its 200-day average, which is falling.
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is NSRX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
NSRX among Drug Manufacturers - General19th of 21 by relative strength
All 21 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | MRK | Stage 2 · wk 16 | 92 | −0.6% |
| 2 | BIIB | Stage 2 · wk 21 | 92 | +11.6% |
| 3 | LLY | Stage 2 · wk 1 | 90 | +13.5% |
| 4 | AMGN | Stage 2 · wk 16 | 87 | +10.1% |
| 5 | OGN | Stage 2 · wk 23 | 87 | +0.1% |
| 6 | BMY | Stage 3 · wk 1 | 85 | +4.1% |
| 7 | JNJ | Stage 2 · wk 16 | 83 | −0.6% |
| 8 | PFE | Stage 2 · wk 8 | 77 | +7.9% |
| …19 | NSRX | Stage 1 · wk 18 | 20 | −11.3% |
Nasus Pharma: quick answers
What stage is Nasus Pharma in?
As of Oct 22, 2026, Nasus Pharma (NSRX) is in Stage 1, the basing phase. It entered Stage 1 on Jun 17, 2026 and is in week 18. What the four stages mean
Is Nasus Pharma in an uptrend?
Not yet. Nasus Pharma is in Stage 1, a base that can come before an uptrend. It trades 14.0% below its 200-day average, which is falling.
How far is Nasus Pharma from its 52-week high?
Nasus Pharma closed at $3.23 on Oct 22, 2026, 64.7% below its 52-week high of $9.15. Its 52-week low is $2.01.
How has Nasus Pharma performed over the past year?
As of Oct 22, 2026, Nasus Pharma is down 57.0% over the past year and down 57.2% so far in 2026.
Which sector and industry is Nasus Pharma in?
Nasus Pharma is in the Drug Manufacturers - General industry, part of the Health Care sector.
About this companyHealth Care· Drug Manufacturers - General
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose. Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.